Imatinib Mesylate and Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

NCT01083589 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Imatinib Mesylate
DRUG: Docetaxel

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]